Stanislaw Burzynski

Stanislaw Rajmund Burzynski was born on January 23, 1943, in Nazi-occupied Lublin, Poland. He earned both his MD and PhD from the Medical Academy in Lublin and emigrated to the United States in 1970, initially working at Baylor College of Medicine. In 1977, he left Baylor to establish his own research laboratory and clinic in Houston, Texas, where he began administering his self-developed 'antineoplastons'—peptides he originally isolated from human blood and urine—as cancer treatments.

From the late 1970s onward, Burzynski attracted thousands of terminally ill cancer patients, particularly children with inoperable brain tumors, charging them enormous sums—sometimes hundreds of thousands of dollars—for treatment that has never received FDA approval. In 1983, a federal court enjoined him from shipping antineoplastons across state lines. In 1994, a federal appeals court affirmed that he had defrauded a health insurer out of $90,000. The FDA raided his clinic twice in the 1990s and a grand jury twice declined to indict him, in highly controversial circumstances that critics attributed to political interference from his substantial Texas political connections.

Burzynski subsequently enrolled patients in dozens of FDA-approved Phase I and II clinical trials as a legal mechanism to continue treatment—a strategy critics characterized as using the trial framework primarily to generate revenue rather than to rigorously test efficacy. At least six study participants died from hypernatremia caused by the sodium-rich antineoplaston formulations; a 2013 FDA clinical hold halted his antineoplaston trials following one such death. The Texas Medical Board filed a 48-page complaint in 2016 alleging Burzynski misled patients, charged excessive fees, failed to disclose conflicts of interest, and billed for unnecessary tests. He reached a settlement that allowed him to keep his license.

No independent researcher has successfully replicated Burzynski's claimed antineoplaston results. The National Cancer Institute, the Japanese National Cancer Institute, and the pharmaceutical company Sigma-Tau Pharmaceuticals all failed to confirm his findings. A 2023 Science-Based Medicine analysis confirmed that he continues to see patients, though the antineoplaston trials remain on FDA clinical hold. Burzynski's case represents a uniquely disturbing intersection of legitimate credentialing, regulatory capture, and the exploitation of vulnerable people facing terminal diagnoses.

“Antineoplastons derived from urine can cure cancer, including inoperable brain tumors”

After over 40 years of investigation, antineoplastons have never been approved by the FDA or any regulatory body for cancer treatment. Studies at the National Cancer Institute and by the pharmaceutical company Sigma-Tau could not replicate Burzynski's claimed results. At least six children died from hypernatremia (sodium poisoning) during his trials.

“Antineoplastons are FDA-approved experimental treatments covered by legitimate clinical trials”

The Texas Medical Board found that Burzynski and staff misled patients into believing they would receive antineoplastons through trials, when most would not qualify. The FDA placed his trials on clinical hold in 2013 following deaths. His 71 concurrent Phase II trials—an unheard-of number for a single investigator—have been criticized as fundamentally flawed in design and execution.